New Phase II data confirm promise of Imunon’s IMMN-001

New Jersey, USA-based Imunon (Nasdaq: IMMN) announced new translational data from the Phase II OVATION 2 Study of IMNN-001, an interleukin-12 (IL-12) DNA-based immunotherapy in development for the treatment of newly diagnosed advanced ovarian cancer. The firm’s shares edged up 3.3% to $0.90 on the news, although they fell back by close of trading.

The results showed a 20% increase in IL-12 levels in women with advanced ovarian cancer treated with IMNN-001 high dose (100mg/m2) plus standard-of-care (SoC) chemotherapy versus IMNN-001 low dose (79mg/m2) plus SoC chemotherapy. Increases in IL-12 levels were primarily in the peritoneal fluid cavity, the primary tumor micro-environment, with little to no changes in the systemic blood stream of treated patients. The rise in IL-12 levels was accompanied by local increases in interferon-gamma and tumor necrosis factor-alphakey downstream anti-cancer immune cytokines.

IMNN-001 continues to demonstrate a favorable safety profile, with no reports of serious immune-related AEs including cytokine release syndrome, the company noted.